Recent clinical trials surrounding the medication Retatrutide , specifically the 120mg formulation branded as ZPHC, indicate a significant effect on weight loss and related metabolic illnesses . Experts anticipate that this innovative agonist , affecting both GLP-1 and GIP systems, has the potential to represent a substantial advance in the managem